Thus, Nar-induced PCSK9 reduction may represent a prospective approach to effectively reduce hypercholesterolemia, avoiding the side effects often complained by statin users [4,45] and the high costs of monoclonal antibodies. This evidence concerns the gene PCSK9 and Hypercholesterolemia.